Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

被引：1
|
作者：
George, Daniel J.
Sternberg, Cora N.
Sartor, A. Oliver
Saad, Fred
Tombal, Bertrand F.
Miller, Kurt
Kalinovsky, Jan
Jiao, XiaoLong
Tangirala, Krishna
Higano, Celestia S.
机构：
[1] Duke Canc Inst, Durham, NC USA
[2] Weill Cornell Med, Englander Inst Precis Med, New York, NY USA
[3] Tulane Med Sch, New Orleans, LA USA
[4] Univ Montreal, Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[5] Clin Univ St Luc, Brussels, Belgium
[6] Charite, Dept Urol, Berlin, Germany
[7] Bayer Healthcare Pharmaceut Inc, Basel, Switzerland
[8] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA
[9] Univ Washington, Seattle, WA 98195 USA
[10] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
253
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Clinical Outcomes With Concurrent or Layered Treatment With Radium-223 and Abiraterone Plus Prednisone/Prednisolone: A Retrospective Study of Real-World Experience With Patients With Metastatic Castration-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 5 - 6
  • [2] Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
    Shore, Neal
    Higano, Celestia S.
    George, Daniel J.
    Sternberg, Cora N.
    Saad, Fred
    Tombal, Bertrand
    Miller, Kurt
    Kalinovsky, Jan
    Jiao, XiaoLong
    Tangirala, Krishna
    Sartor, Oliver
    PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (04) : 680 - 688
  • [3] Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
    Neal Shore
    Celestia S. Higano
    Daniel J. George
    Cora N. Sternberg
    Fred Saad
    Bertrand Tombal
    Kurt Miller
    Jan Kalinovsky
    XiaoLong Jiao
    Krishna Tangirala
    Oliver Sartor
    Prostate Cancer and Prostatic Diseases, 2020, 23 : 680 - 688
  • [4] Concurrent or layered treatment with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Shore, Neal D.
    Sartor, A. Oliver
    Sternberg, Cora N.
    Saad, Fred
    Tombal, Bertrand F.
    Miller, Kurt
    Kalinovsky, Jan
    Jiao, XiaoLong
    Tangirala, Krishna
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Shore, Neal D.
    Sartor, Oliver A.
    Sternberg, Cora N.
    Saad, Fred
    Tombal, Bertrand F.
    Miller, Kurt
    Kalinovsky, Jan
    Jiao, Xiaolong
    Tangirala, Krishna
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [6] A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
    Kim, Stephanie, I
    Szeto, Andy H.
    Morgan, Katherine P.
    Brower, Blaine
    Dunn, Mary W.
    Khandani, Amir H.
    Godley, Paul A.
    Rose, Tracy L.
    Basch, Ethan M.
    Milowsky, Matthew, I
    Whang, Young E.
    Crona, Daniel J.
    PLOS ONE, 2021, 16 (06):
  • [7] Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patients
    Miyoshi, Yasuhide
    Yasui, Masato
    Ttsutsumi, Sohgo
    Kawahara, Takashi
    Uemura, Ko-ichi
    Hayashi, Naruhiko
    Nozawa, Masahiro
    Yoshimura, Kazuhiro
    Uemura, Hiroji
    Uemura, Hirotsugu
    BJUI COMPASS, 2021, 2 (01): : 31 - 38
  • [8] UTILIZATION OF RADIUM-223 DICHLORIDE (RA-223) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CANADA: A REAL-WORLD RETROSPECTIVE STUDY
    Lapierre, M.
    Fraelic, A.
    VALUE IN HEALTH, 2016, 19 (03) : A162 - A162
  • [9] Radium-223 in metastatic castration-resistant prostate cancer (mCRPC):efficacy and safety in real-life experience
    Rebuzzi, S. E.
    Prelaj, A.
    Pozzi, C.
    Ferrara, C.
    Frantellizzi, V.
    Follacchio, G. A.
    de Vincentis, G.
    Tomao, S.
    Bianco, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Radium-223 In The Treatment Of Metastatic Castration-Resistant Prostate Cancer
    Vazzana, C.
    Morano, S.
    Di Lascio, A.
    Grana, C.
    Chinol, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S880 - S880
12345